Crossject Société Anonyme Company Description

Crossject Société Anonyme develops needle-free injection systems in France.

The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables.

Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis.

The company was founded in 2001 and is based in Dijon, France.

Crossject Société Anonyme

Country	France
Founded	2001
Industry	Medical Instruments & Supplies
Sector	Healthcare
Employees	105
CEO	Patrick Alexandre

Contact Details

Address: 6 Rue Pauline Kergomard Dijon, 21000 France
Phone	33 3 80 54 98 50
Website	crossject.com

Stock Details

Ticker Symbol	ALCJ
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0011716265
SIC Code	3841

Key Executives

Name	Position
Patrick Alexandre	Co-Founder, Chief Executive Officer and Chairman of the Executive Board
Dr. Isabelle Liebschütz	Chief Quality and Regulatory Officer and Member of Executive Board
Olivier Giré	Chief Operating Officer of Specialty Pharma and Member of Executive Board
Dr. Dan Chiche M.D.	Chief Medical Officer North America
Tony Tipton	Chief Operating Officer of U.S